Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Mayne Pharma (MYX AU)
Watchlist
225
Analysis
Health Care
•
Australia
Mayne Pharma Group Ltd. develops and manufactures oral pharmaceuticals. The Company produces branded generics, specialty generics, and active pharmaceutical ingredients.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Santos Ltd
•
22 Jun 2025 06:10
(Mostly) Asia-Pac M&A: Adriatic Metals, Carta, Mayne Pharma, PointsBet, Tourism Holdings
This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...
David Blennerhassett
Follow
594 Views
Share
bearish
•
Mayne Pharma
•
18 Jun 2025 15:53
Mayne Pharma (MYX AU): Entering Uncharted Territory as the Scheme Vote Passes
While Western case law burdens the buyer with establishing a MAC breach, the Mayne/Cosette court case wades into uncharted territory, bringing many...
Arun George
Follow
672 Views
Share
bullish
•
Mayne Pharma
•
18 Jun 2025 14:45
Mayne Pharma (MYX AU): The Vote Gets Up. Now What?
The possibility of an agreed price reduction has reduced; but arguably, so has the MAC threat. Only the facts presented during the court hearing...
David Blennerhassett
Follow
675 Views
Share
bullish
•
Mayne Pharma
•
16 Jun 2025 14:37
Mayne Pharma: No Precedence for a Deal Termination
Cosette signed a binding agreement to acquire Mayne Pharma (MYX) for $7.40 per share. Cosette, predictably got cold feet and is attempting to...
Nicholas Tan
Follow
601 Views
Share
bearish
•
Mayne Pharma
•
16 Jun 2025 01:23
Merger Arb Mondays (16 June) - Mayne, Pointsbet, Fengxiang, HKBN, Seven & I, Shibaura, Smartpay
We summarise the latest spreads and newsflow of merger arb situations we cover across Hong Kong, Australia, New Zealand, Singapore, Japan,...
Arun George
Follow
1k Views
Share
First
Previous
20
21
22
23
24
25
26
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x